Literature DB >> 10426581

Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma secreting thyrotropin, growth hormone and prolactin.

A Shimatsu1, H Murabe, Y Nakamura, H Mizuta, C Ihara, K Nakao.   

Abstract

A 48-year-old female presented with acromegaly, amenorrhea and hyperthyroidism associated with high serum free T4 levels and measurable TSH concentrations. The administration of GHRH induced significant increases in GH, PRL and TSH. Conversely, intravenous infusion of dopamine or oral administration of bromocriptine effectively inhibited GH, PRL and TSH secretion. Serum alpha-subunit levels were neither affected by GHRH, dopamine nor bromocriptine. Transsphenoidal surgery was performed and immunostaining of the tissue showed that the adenoma cells were positive for GH, PRL or TSH. The patient was treated with bromocriptine at a daily oral dose of 10 mg after surgery. Serum TSH were initially suppressed but returned within reference intervals with persistent normalized free T4 levels. Serum PRL became undetectable and GH levels were stable around 6 ng/ml except the periods of poor drug compliance, when serum TSH, GH and PRL levels rose considerably. The patient was followed-up for 10 years without any change in the residual adenoma tissues as detected by magnetic resonance imaging. These findings suggest that long-term bromocriptine therapy is effective in treating the hypersecretory state of a plurihormonal adenoma secreting TSH, GH and PRL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10426581     DOI: 10.1507/endocrj.46.159

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  2 in total

1.  In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5.

Authors:  Federico Gatto; Federica Barbieri; Lara Castelletti; Marica Arvigo; Alessandra Pattarozzi; Francesca Annunziata; Alexandru Saveanu; Francesco Minuto; Lucio Castellan; Gianluigi Zona; Tullio Florio; Diego Ferone
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107

2.  Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy.

Authors:  I Shimon; D Nass; D J Gross
Journal:  Pituitary       Date:  2001-09       Impact factor: 4.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.